Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451312 | 0.91 | POLB (0.63) | LOXL2NAMPTMAPTLMNAHPGD | |
| SCHEMBL14049770 | 0.86 | AKR1C3 (0.52) | CYP4F2CYP4A11NAMPTMAPTLMNA | |
| SCHEMBL13628247 | 0.86 | NAMPT (0.55) | LOXL2CYP4F2CYP4A11NAMPTMAPT | |
| SCHEMBL3012713 | 0.83 | LOXL2 (0.76) | LOXL2CYP4F2CYP4A11MAPTHPGD | |
| SCHEMBL14049769 | 0.83 | NAMPT (0.52) | LOXL2CYP4F2CYP4A11NAMPTMAPT | |
| Hydrochloric Acid SCHEMBL4447485 | 0.82 | LOXL2 (0.73) | LOXL2CYP4F2CYP4A11MAPTHPGD | |
| SCHEMBL8705459 | 0.80 | LOXL2 (0.56) | LOXL2CYP4F2CYP4A11MAPTPOLB | |
| SCHEMBL3871576 | 0.80 | POLB (0.78) | NAMPTMAPTLMNAHPGDPOLB | |
| SCHEMBL3872490 | 0.80 | CYP19A1 (0.68) | LOXL2CYP4F2CYP4A11NAMPTMAPT | |
| SCHEMBL3874748 | 0.79 | NAMPT (0.60) | LOXL2NAMPTMAPTLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008127364-A2 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | LOXL2 4050/4885CYP4F2 3246/4885CYP4A11 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.